Compare Entegris Inc (ENTG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Viatris Inc — how do they compare? Entegris Inc trades at $134.19 (market cap $21.12B), while Viatris Inc trades at $17.32 (market cap $19.44B). The key difference: Entegris Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| ENTG | VTRS | |
|---|---|---|
Market Cap | $21.12B | $19.44B |
Sector | Technology | Health |
52-Week High | $184.00 | $17.39 |
52-Week Low | $68.80 | $8.74 |
Enterprise Value | $24.44B | $31.65B |
Dividend Yield | 0.29% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $134.15, down 4.61% today, with technical indicators showing bearish momentum as the stock approaches key support at $133. The company maintains solid fundamentals with Q1 2026 earnings beating estimates at $0.86 per share and strong analyst consensus of 65% buy ratings. Recent developments include a $0.10 dividend declaration and new CFO appointment, while semiconductor industry tailwinds from AI-driven demand provide growth catalysts.
ENTG presents a compelling opportunity with 25% upside to the $178.40 consensus price target, supported by improving cash flow trends and semiconductor sector growth. However, elevated valuation multiples (P/E 80.17) and technical bearish signals warrant caution amid recent price volatility and competitive pressures in the semiconductor materials space.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
